DOI: https://doi.org/10.36347/sjmcr.2024.v12i08.032

Pages: 1489-1495

Adenoid cystic carcinoma of the parotid gland is a rare, slow-growing malignancy characterized by extensive local infiltration, including perineural invasion and a propensity for local recurrence, as well as late distant metastases. Clinically, it is often expressed as swelling of the parotid region with or without facial paralysis. The diagnosis is histopathological. The standard of care is surgery, with radiotherapy and chemotherapy as options. We conducted a retrospective study of four cases who were treated for ACC of the parotid at the Department of Oncology-Radiotherapy of the Mohammed VI University Hospital of Marrakech between 2019 and 2024. Our patients benefited from partial surgery followed by radiotherapy (Patients 1 and 3), exclusive radiotherapy (Patient 2) and total surgery followed by chemotherapy (Patient 4) with encouraging responses. Maintaining the time limit between therapies is a major challenge in developing countries because, faced with technical, logistical, social and above all financial difficulties, our patients who benefited from post-operative radiotherapy did not respect this deadline. Currently, our patients are under surveillance. As recurrences and metastases occur late, this monitoring must last several years (more than 10 years).